Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma

Melanoma Research

Volumn 27, Issue 4, 2017, Pages 335-341

  Leon Ferre, Roberto A ^a   Kottschade, Lisa A ^a   Block, Matthew S ^a   McWilliams, Robert R ^a   Dronca, Roxana S ^a   Creagan, Edward T ^a   Allred, Jacob B ^a   Lowe, Val J ^b   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

^b Departments of Radiology   (Australia)

Author keywords

Melanoma; PET CT; recurrence; resection; salvage; surveillance

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; IPILIMUMAB; PEPTIDE VACCINE; RESIQUIMOD; TEMOZOLOMIDE;

ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISTANT METASTASIS; EVALUATION STUDY; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; WHOLE BODY CT; WHOLE BODY PET; DIAGNOSTIC IMAGING; PATHOLOGY; PROCEDURES; SKIN TUMOR; TUMOR RECURRENCE;

FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 85015152061     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000344     Document Type: Article

References (12)

1. Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol 2004; 86:172-178.
2. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: Implications for follow-up guidelines. J Clin Oncol 2010; 28:3042-3047.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7-30.
4. Wasif N, Bagaria SP, Ray P, Morton DL. Does metastasectomy improve survival in patients with stage IV melanoma A cancer registry analysis of outcomes. J Surg Oncol 2011; 104:111-115.
5. Ollila DW, Gleisner AL, Hsueh EC. Rationale for complete metastasectomy in patients with stage IV metastatic melanoma. J Surg Oncol 2011; 104:420-424.
6. Ollila DW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol 2006; 7:919-924.
7. Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: Recommendations for an effective follow-up strategy. J Clin Oncol 2003; 21:520-529.
8. Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, et al. Followup recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 1999; 86:2252-2258.
9. Meyers MO, Yeh JJ, Frank J, Long P, Deal AM, Amos KD, Ollila DW. Method of detection of initial recurrence of stage II/III cutaneous melanoma: Analysis of the utility of follow-up staging. Ann Surg Oncol 2009; 16:941-947.
10. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based Ann Surg 1995; 221:566-569. discussion 569-571.
11. Lewin JH, Sanelli A, Walpole I, Kee D, Henderson MA, Speakman D, et al. Surveillance imaging with FDG-PET in the follow-up of melanoma patients at high risk of relapse. J Clin Oncol 2015; 33:9003.
12. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: A meta-analysis. J Natl Cancer Inst 2011; 103:129-142.